Caplacizumab, with a cosine similarity score of 0.294, is approved for treating adult acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood disorder caused by an autoantibody-mediated severe deficit in the von Willebrand factor (vWF) cleaving metalloproteinase ADAMTS13 [23]. Here, VWF is linked to hematologic disorder.